PlainRecalls
FDA Drug Critical Class I Terminated

Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL Single Dose Vial, Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540; Manufactured by: EBEWE Pharma Ges.m.b.H. Nfg.KG, A-4866 Unterach, AUSTRIA, NDC 66758-041-01.

Reported: August 14, 2013 Initiated: May 20, 2013 #D-832-2013

Product Description

Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL Single Dose Vial, Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540; Manufactured by: EBEWE Pharma Ges.m.b.H. Nfg.KG, A-4866 Unterach, AUSTRIA, NDC 66758-041-01.

Reason for Recall

Presence of Particulate Matter: Found during examination of retention samples.

Details

Recalling Firm
Sandoz Incorporated
Units Affected
1,635 vials
Distribution
Nationwide
Location
Broomfield, CO

Frequently Asked Questions

What product was recalled?
Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL Single Dose Vial, Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540; Manufactured by: EBEWE Pharma Ges.m.b.H. Nfg.KG, A-4866 Unterach, AUSTRIA, NDC 66758-041-01.. Recalled by Sandoz Incorporated. Units affected: 1,635 vials.
Why was this product recalled?
Presence of Particulate Matter: Found during examination of retention samples.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 14, 2013. Severity: Critical. Recall number: D-832-2013.